Addex Moves R&D Operations to Geneva's Campus Biotech
December 07, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, December 7, 2015 -...
Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program
November 25, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 25 November 2015...
Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
November 23, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 23 November...
ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share
November 19, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 19 November...
Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
October 13, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Successful collaboration with the US...
Addex Therapeutics Reports First Half 2015 Financial Results
September 30, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 30 September 2015...
Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
September 23, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 23 September 2015...
Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field
September 08, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Addex Grants Option to License mGlu3...
Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics
August 17, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 17 August 2015 -...
Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's Disease
August 14, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland 14 August 2015...